Trials / Withdrawn
WithdrawnNCT05796167
Pimavanserin for Sleep in Parkinson Disease
Does Pimavanserin (Nuplazid) Improve Sleep in Patients With Parkinson Disease Psychosis? A Pilot Study
- Status
- Withdrawn
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- State University of New York - Downstate Medical Center · Academic / Other
- Sex
- All
- Age
- 40 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This pilot, self-control study is for patients with Parkinson's Disease (PD) psychosis (e.g., visual hallucinations, delusions) and sleep problems.
Detailed description
This is a feasibility study to determine whether pimavanserin improves sleep quality in patients with PD and visual hallucinations/delusions. Patients will complete a Screening Visit to assess eligibility to participate in the study. For more information, please contact Sofya Glazman, a study coordinator, at sofya.glazman@downstate.edu
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pimavanserin | Pimavanserin (Nuplazid) 34 mg oral capsules once a day for 6 weeks |
Timeline
- Start date
- 2023-01-27
- Primary completion
- 2024-06-24
- Completion
- 2024-06-24
- First posted
- 2023-04-03
- Last updated
- 2024-12-20
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05796167. Inclusion in this directory is not an endorsement.